Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
End stage kidney disease
How should PPIs or H2 blockers be managed in peritoneal dialysis patients with a history of peritonitis and peptic ulcer disease, considering the potential infection risk?
Related Questions
Do you favor peritoneal dialysis over hemodialysis in patients with an LVAD who have ESKD?
How would you counsel a patient with CKD Stage 5 and prediabetes who is concerned about their risk of developing diabetes if they start peritoneal dialysis?
Do you recommend prophylactically adding heparin to the dialysate in patients hospitalized for peritoneal dialysis associated peritonitis given higher incidence of fibrin-associated catheter issues?
Do you prefer automated peritoneal dialysis during the day or night for a hospitalized patient with ESKD on PD?
Would you refer an ESKD patient with an identified living donor for AV access placement if kidney transplantation is anticipated in 4 months?
Do you recommend first consulting interventional radiology or vascular surgery if you lack access to interventional nephrology in a patient with ESKD who is suspected of having a clotted fistula and is unable to receive hemodialysis?
How do you approach recommending an AVF for a patient with advanced CKD who is concerned about the cosmetic appearance of the fistula?
What medications do you use to treat encapsulating peritoneal sclerosis?
Which ESKD patients would you consider transitioning from hemodialysis to hemodiafiltration, given the FDA approval of a hemodiafiltration system in the US?
Do you recommend avoiding ESAs in ESKD patients with heart failure who require a left ventricular assist device?
